Security Snapshot

Vor Biopharma Inc. - Common Stock, par value $0.0001 per share (VOR) Institutional Ownership

CUSIP: 929033207

13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

107

Shares (Excl. Options)

40.23MFull value: 40,225,779 · shares · 30 Sep 2026

Price

$19.08

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+3,688,173
Value change
+$71,592,144
Number of holders
107
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
61,663,891
SEC-reported price per share
$20.91
Insider filing price
$20.91
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • VOR - Vor Biopharma Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 929033207.
  • 107 institutions reported positions in Q3 2026.
  • 12 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 102 to 107 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $893.03MFull value: $893,029,544 · USD · 30 Jun 2026
    to
    $767.94MFull value: $767,941,164 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 107 institutions filings for Q3 2026.

Open SEC evidence

Security key

929033207

13F reference period

Q3 2026

13F holders

107

13D/G owners

12

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
12
Security
VOR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 20% +42% $238,185,911 +$138,559,809 12,937,855 +139% RA Capital Management, L.P. 16 Jul 2026
ForGrowth III PA B.V. 10% 0% $81,492,203 +$25,772,203 10,237,714 +46% ForGrowth III PA B.V. 18 Dec 2025
Venrock Healthcare Capital Partners III, L.P. 9.9% 0% $134,736,073 +$16,043,177 6,443,619 +14% Venrock Healthcare Capital Partners III, L.P. 30 Sep 2026
FMR LLC 11% -11% $117,398,194 -$3,557,531 6,318,525 -2.9% FMR LLC 30 Sep 2026
TCG Crossover GP II, LLC 9.2% $118,624,061 5,673,078 Chen Yu 30 Sep 2026
Verve Capital Ltd 6.3% -33% $67,365,117 -$31,370,505 3,410,892 -32% Verve Capital Limited 30 Jun 2026
BlackRock, Inc. 5.7% $57,057,358 3,099,259 BlackRock, Inc. 30 Jun 2026
Frazier Life Sciences Public Fund, L.P. 4.2% -27% $44,595,520 2,258,001 0% Frazier Life Sciences Public Fund, L.P. 30 Jun 2026
Paradigm Biocapital Advisors LP 4.5% -46% $23,730,000 1,750,000 0% Paradigm BioCapital Advisors LP 31 Dec 2025
GREAT POINT PARTNERS LLC 3.3% -39% $18,578,651 +$1,839,021 1,370,107 +11% Great Point Partners, LLC 31 Dec 2025
Reprogrammed Interchange LLC 18% $48,045,191 1,204,442 Reprogrammed Interchange LLC 15 Oct 2025
Qiming Venture Partners VIII-HC, L.P. 2% -27% $19,670,294 1,089,767 0% Qiming Venture Partners VIII-HC, L.P. 31 Mar 2026
As of 30 Sep 2026, 107 institutional investors reported holding
40.23MFull value: 40,225,779 · shares · 30 Sep 2026
shares of Vor Biopharma Inc. - Common Stock, par value $0.0001 per share (VOR). This represents 65% of the company’s total
61.66MFull value: 61,663,891 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
58%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TCG Crossover Management, LLC 9.2% 5,673,078 3.1% $108,242,328
RA CAPITAL MANAGEMENT, L.P. 7.3% 4,503,882 0.86% $85,934,069
FCPM III SERVICES B.V. 5.5% 3,405,279 6.1% $64,972,723
Venrock Adviser, LLC 4.9% 3,041,719 2.8% $58,035,999
Frazier Life Sciences Management, L.P. 4.4% 2,743,939 1.3% $52,354,356
VANGUARD CAPITAL MANAGEMENT LLC 3.3% 2,035,477 0% $38,836,901
STATE STREET CORP 3.2% 1,969,801 0% $37,583,803
Caligan Partners LP 3.1% 1,925,066 2.2% $36,730,259
GREAT POINT PARTNERS LLC 1.8% 1,126,910 5.6% $21,501,443
GEODE CAPITAL MANAGEMENT, LLC 1.6% 979,890 0% $18,701,443
Nantahala Capital Management, LLC 1.5% 931,644 1% $17,775,768
Paradigm Biocapital Advisors LP 1.4% 889,575 0.34% $16,973,091
FEDERATED HERMES, INC. 1.2% 760,221 0.02% $14,505,017
GOLDMAN SACHS GROUP INC 1.2% 746,214 0% $14,237,763
NAN FUNG TRINITY (HK) LTD 1.2% 721,550 1.3% $13,767,174
NEXTBio Capital Management LP 1% 620,931 5.1% $11,847,363
MARSHALL WACE, LLP 0.91% 560,715 0.01% $10,698,439
Vivo Capital, LLC 0.89% 550,358 1.2% $10,500,831
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.79% 490,000 0.01% $9,349,200
SPHERA FUNDS MANAGEMENT LTD. 0.62% 383,417 1.1% $7,315,596
Integral Health Asset Management, LLC 0.57% 350,000 0.42% $6,678,000
Point72 Asset Management, L.P. 0.56% 343,037 0.01% $6,545,146
VANGUARD PORTFOLIO MANAGEMENT LLC 0.54% 333,308 0% $6,359,517
BRAIDWELL LP 0.52% 319,308 0.25% $6,092,397
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.49% 300,529 0.01% $5,734,093

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
5
Headline period
Q3 2026
Rows shown
1-5 of 5
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 40,225,779 $767,941,164 +$71,592,144 $19.08 107
2026 Q2 48,507,381 $893,029,544 +$148,816,693 $18.41 102
2026 Q1 40,448,699 $716,851,001 +$247,955,353 $17.84 80
2025 Q4 25,547,116 $332,020,908 +$261,622,068 $13.08 54
2025 Q3 3,710,338 $180,767,786 +$180,382,226 $48.72 35
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .